- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00615927
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma
Primary objective:
- To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival
Secondary objectives:
- To evaluate progression-free survival (PFS), overall survival and objective response rate among patients with progressive/recurrent grade II LGG treated with imatinib mesylate plus hydroxyurea
- To assess safety and tolerability of imatinib mesylate + hydroxyurea in this population
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with grade II LGG that is recurrent/progressive following prior surgical resection while on non-decreasing dose of corticosteroids
- > 25percent enlargement of bidimensional measure/new lesions on sequential imaging new &/or worsening neurologic deficits
- Patients with progressive/recurrent optic pathway tumors
- Patients have measurable disease on MRI/CT
- Interval of > 4 wks between prior external beam radiation therapy (XRT)/chemo,& enrollment on protocol unless there is unequivocal evidence of tumor progression & patient has recovered from all expected toxicities associated with prior therapy. Patients treated w chemo agents such as VP-16 who would normally be retreated after shorter intervals may be treated at usual starting time even if < 4 wks from last prior dose of chemo
- Patients not have had tumor biopsy < 1 wk/surgical resection < 2 wks prior to starting study drug
- Patients enrolling on arm B must be on > 1 enzyme inducing anticonvulsants for >2 wks prior to starting study drug
- Patients should be on non-increasing dose of steroids for > 7 days prior to obtaining baseline Gd-MRI of brain
- Patients should be on non-increasing dose of steroids for > 7 days prior to starting study drug
- Multifocal disease is eligible
- Age > 18 yrs old
- Karnofsky Performance Status (KPS) of > 60
- absolute neutrophil count (ANC) > 1.5 x 10 9/L
- Hgb > 9 g/dL
- Platelets > 100 x 10 9/L
- K ≥ lower limit of normal (LLN)/correctable with supplements
- Ca ≥ LLN/correctable with supplements
- P ≥ LLN/correctable with supplements
- aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) & Alanine transaminase (ALT)/ Serum Glutamic Pyruvate Transaminase (SGPT} < 2.5 x ULN
- Serum bilirubin < 1.5 x upper limit of normal (ULN)
- Serum creatinine < 1.5 x ULN/measured 24hr Creatinine Clearance > 50 mL/min/1.73m2
- Life expectancy ≥ 12wks
- Written informed consent obtained prior to screening procedures
Exclusion Criteria:
- Prior progressive disease/toxicity grade ≥ 3 with prior hydroxyurea therapy
- Prior treatment with imatinib/other platelet derived growth factor (PDGF)-directed therapy
- Excessive risk of bleeding as defined by stroke < 6 months, history of central nervous system (CNS)/intraocular bleed, or septic endocarditis
- Evidence of intratumor hemorrhage on pretreatment diagnostic imaging, except for stable post-operative gr1 hemorrhage
- Pregnant/breast feeding, /adults of reproductive potential not employing effective method of birth control
- Concurrent severe and/or uncontrolled medical disease that could compromise participation in study
- Acute/chronic liver disease
- Confirmed diagnosis of HIV infection
- Impairment of GI function/GI disease that may significantly alter absorption of imatinib
- Patients taking Coumadin
- Patients have received investigational drugs < 2wks prior to entry on study/have not recovered from toxic effects of such therapy
- Patients have received biologic, immunotherapeutic/cytostatic agents < 1 wk prior to entry on study/have not recovered from toxic effects of such therapy
- Patient > 5 yrs free of another primary malignancy except: if other primary malignancy is not currently clinically significant/requiring active intervention, or if other primary malignancy is basal cell skin cancer/ cervical carcinoma in situ. Existence of any other malignant disease is not allowed
- Patients have had any surgery other than resection of brain tumor < 2 wks prior to entry on study/have not recovered from side effects of such therapy
- Patients unwilling to/unable to comply with protocol
- Active systemic bleeding, such as GI bleeding/gross hematuria
- Gr2 /> peripheral edema/central/systemic fluid collections
- Patients who enroll on arm A must have not received any EIAC for > 2 wks prior to starting study regimen
Any of following exclusion criteria to MRI imaging:
- Cardiac pacemaker
- Ferromagnetic metal implants other than those approved as safe for use in magnetic resonance (MR) scanners
- Claustrophobia
- Obesity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Astrocytoma
Grade II Astrocytoma
|
Imatinib administered orally on daily. Imatinib is local irritant & must be taken in sitting position; mini of 2hrs should be allowed between last drug intake & going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues. Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 & continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.
Other Names:
|
Experimental: Oligodendroglioma
Grade II Oligodendroglioma or oligoastrocytomas
|
Imatinib administered orally on daily. Imatinib is local irritant & must be taken in sitting position; mini of 2hrs should be allowed between last drug intake & going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues. Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 & continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-month Progression Free Survival (PFS)
Time Frame: 12 months
|
Percentage of participants surviving twelve months from the start of cycle 1 without progression of disease.
PFS was defined as the time from the cycle 1 start date to the date of the first documented progression according to modified Macdonald criteria, or to death due to any cause.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-free Survival
Time Frame: Time in weeks from the start of cycle 1 to the date of first progression according to modified Macdonald criteria or to death due to any cause, assessed up to 156 weeks
|
Time in weeks from the start of cycle 1 to the date of first progression according to modified Macdonald criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date.
Median PFS was estimated using a Kaplan-Meier curve.
|
Time in weeks from the start of cycle 1 to the date of first progression according to modified Macdonald criteria or to death due to any cause, assessed up to 156 weeks
|
Median Overall Survival (OS)
Time Frame: Time in weeks from the start of cycle 1 to date of death due to any cause, assessed up to 156 weeks
|
Time in weeks from the start of cycle 1 to date of death due to any cause.
Patients alive at last follow-up are censored as of that follow-up date.
Median OS was estimated using a Kaplan-Meier curve.
|
Time in weeks from the start of cycle 1 to date of death due to any cause, assessed up to 156 weeks
|
Objective Response Rate
Time Frame: 156 weeks
|
Number of participants with an objective response (complete response or partial response) based on modified Macdonald criteria.
|
156 weeks
|
Safety and Tolerability of Gleevec + Hydroxyurea in Patients With Low-grade Gliomas
Time Frame: 156 weeks
|
The number of patients experiencing any serious adverse event or other (non-serious) adverse event during the study participation.
|
156 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Gliosarcoma
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Antisickling Agents
- Imatinib Mesylate
- Hydroxyurea
Other Study ID Numbers
- Pro00008799
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Imatinib Mesylate & Hydroxyurea
-
Istituto Scientifico H. San RaffaeleUnknownBrain and Central Nervous System TumorsItaly
-
Annick DesjardinsAstraZeneca; Novartis PharmaceuticalsCompletedGlioblastoma | GliosarcomaUnited States
-
Annick DesjardinsNovartis PharmaceuticalsCompletedGlioblastoma | GliosarcomaUnited States
-
Duke UniversityNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedGlioblastoma | GliosarcomaUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
First Affiliated Hospital of Harbin Medical UniversityUnknownLeukemia, Chronic MyeloidChina
-
Novartis PharmaceuticalsCompletedAstrocytoma | Glioblastoma MultiformeGermany
-
NovartisTerminatedRecurrent Glioblastoma Multiforme (GBM)United States
-
University of LeipzigCompletedLeukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina